Literature DB >> 30802932

Oncology Therapy Drugs in China, Japan, and the United States: Pharmacokinetic Characteristics, Dose Regimens, and Development Strategies.

Li Zhou1, Mitsuo Higashimori2, Kai Shen3, Zhenxian Zhang3, Jennifer Sheng4, Hongmei Xu1, Masato Horiuchi2, Katsuomi Ichikawa2, Nidal Al-Huniti1, Diansong Zhou1.   

Abstract

Year:  2019        PMID： 30802932     DOI： 10.1002/cpt.1352

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  3 in total

1.  Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.

Authors:  Colby S Shemesh; Phyllis Chan; Hui Shao; Derek-Zhen Xu; Daniel Combs; Shweta Vadhavkar; René Bruno; Benjamin Wu
Journal:  Liver Cancer       Date:  2021-06-10       Impact factor: 11.740

2.  Surveys/Research Exploring Japanese Phase I Studies in Global Drug Development: Are They Necessary Prior to Joining Global Clinical Trials?

Authors:  Masaru Hirano; Masanori Yamada; Toshiaki Tanaka; Toshiko Koue; Tomohisa Saito; Mitsuo Higashimori; Hisao Ochiai; Junichi Yamamoto; Saori Yaguchi; Sachiko Mita; Katsutoshi Hara
Journal:  Clin Pharmacol Drug Dev       Date:  2021-11-26

3.  Clinical Benefit-Risk Assessment of Nivolumab 240 mg Every 2 Weeks in Chinese Patients With Advanced and Metastatic Solid Tumors.

Authors:  Jennifer Sheng; Jason Zhang; Christine Baudelet; Amit Roy
Journal:  J Clin Pharmacol       Date:  2021-02-14       Impact factor: 3.126
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.